This episode delves into the critical reimbursement gap facing innovative medical devices in the United States. We explore why FDA Breakthrough Device designation doesn't guarantee Medicare payment, the financial "valley of death" this creates for MedTech startups, and how the proposed "Ensuring Patient Access to Critical Breakthrough Products Act" aims to provide a vital four-year bridge of temporary coverage.

- What is the FDA's Breakthrough Devices Program?

- Why does FDA approval not automatically lead to Medicare reimbursement?

- What is the "reimbursement valley of death" for MedTech innovators?

- How does the evidence required by the FDA differ from that required by CMS?

- What was the MCIT rule and why was its 2021 repeal significant?

- What is the "Ensuring Patient Access to Critical Breakthrough Products Act"?

- How does the proposed four-year transitional coverage period work?

- Why is this legislation critical for medical innovation and patient access?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient pathways for regulatory approval, leveraging advanced AI to compile and submit technical dossiers that minimize rejections. Our experts act as your local representative in over 30 markets, helping you identify the best regions for expansion and ensuring your innovative products reach patients faster. Whether you are a startup or a multinational enterprise, our technology-driven solutions are tailored to your needs. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.

This episode delves into the growing use of agentic AI for drafting complex regulatory dossiers like FDA 510(k)s and EU Technical Files. We explore the paradox where AI's speed in drafting is offset by a massive bottleneck: the intensive, time-consuming process of human-in-the-loop validation. Discover why this crucial verification step is non-negotiable and how it's reshaping the role of regulatory professionals, preventing the promised acceleration to market.

Key Questions:

- What is "agentic AI" and how is it changing MedTech regulatory submissions?

- Why is the dream of fully automated dossier creation still out of reach?

- What is the "human-in-the-loop" validation bottleneck and why is it critical?

- How can you leverage AI's power for submissions without compromising on compliance?

- What are the legal and practical risks of over-relying on AI for regulatory files?

- Is your regulatory team prepared for the new skills needed to manage AI tools?

- How does a balanced "co-pilot" approach to AI optimize your submission strategy?

Pure Global helps MedTech and IVD companies navigate these modern regulatory challenges. We combine deep local expertise with advanced AI tools to streamline your global market access. Our services assist in developing efficient regulatory strategies and compiling technical dossiers, ensuring accuracy while leveraging technology to accelerate processes. Instead of getting bogged down by validation, let our experts and AI-powered platforms manage your submissions efficiently across more than 30 markets. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to learn more.

This episode explores the growing threat of 'digital darkness'—total network outages caused by cyberattacks—and its impact on the medical device industry. We delve into the heightened scrutiny from regulatory bodies like the FDA and under the EU MDR, focusing on new requirements for manufacturers to prove their devices can function safely and effectively offline. We discuss key strategies for building cybersecurity resilience, from design and risk assessment to post-market surveillance.

Key Questions

- What is "digital darkness" and why is it a top concern for hospitals?

- How are the FDA and EU regulators changing their cybersecurity requirements for medical devices?

- What must manufacturers now demonstrate about their device's offline capabilities?

- Why has a Software Bill of Materials (SBOM) become a critical submission document?

- What are effective strategies for designing devices that are resilient to network failure?

- How does post-market surveillance play a role in managing cybersecurity risks?

- What are the consequences for manufacturers who fail to meet these new standards?

Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, ensuring your products meet complex global standards, including cybersecurity. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, helping you navigate demanding requirements from bodies like the FDA and EU. We act as your local representative in over 30 markets, managing the entire lifecycle from initial submission to post-market surveillance. Let us help you achieve faster global market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the pivotal shift from traditional clinical trial data to the increasing demand for continuous Real-World Evidence (RWE) for medical devices. We delve into why global regulators and payers now require robust post-market data to prove a device's long-term safety, effectiveness, and value. We also unpack the significant infrastructure and analytical challenges that MedTech companies face in building a compliant and effective RWE program.

Key Questions:

- What is the difference between Real-World Data (RWD) and Real-World Evidence (RWE)?

- Why are traditional clinical trials no longer sufficient for market approval and reimbursement?

- How do new regulations like the EU MDR impact post-market data collection requirements?

- What specific evidence are payers looking for to determine a device's cost-effectiveness?

- What are the main challenges companies face when building an RWE generation system?

- How can a strong RWE strategy provide a competitive advantage?

As regulatory demands for Real-World Evidence intensify, having a proactive strategy is essential. Pure Global helps MedTech and IVD companies design and implement robust post-market surveillance and data analysis programs. Our blend of local regulatory expertise and advanced AI tools simplifies the process of gathering, analyzing, and submitting the evidence needed to maintain and expand global market access. We turn your post-market obligations into a strategic advantage. To learn more about our services, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the EU's new Artificial Intelligence Act and its significant impact on medical device manufacturers. We explore the "high-risk" classification for most AI-driven medical devices, the new compliance obligations that run parallel to existing MDR/IVDR requirements, and the critical timelines manufacturers must meet. We break down the challenges and strategies for navigating this dual regulatory framework, from data governance to human oversight.

- What is the EU AI Act and why is it critical for MedTech companies?

- How are AI-powered medical devices classified under this new regulation?

- What are the new, specific compliance requirements beyond MDR and IVDR?

- How does the conformity assessment process work for both the AI Act and MDR/IVDR?

- Are you required to get two separate certifications?

- What is the key compliance deadline that all manufacturers must have on their calendar?

- How should you prepare your Quality Management System and technical documentation for this dual framework?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your products approved faster. Our AI-powered platforms help compile and manage technical dossiers for seamless submissions to authorities in the EU and beyond. Whether you're a startup or a multinational, we provide tailored solutions for market access and continuous compliance. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode breaks down the FDA's final rule transitioning the Quality System Regulation (21 CFR Part 820) to the ISO 13485-aligned Quality Management System Regulation (QMSR). We cover the February 2, 2026, compliance deadline, the key differences and retained FDA requirements, and the strategic steps medical device manufacturers must take to harmonize their global quality documentation and ensure a seamless transition.

- What is the FDA's new Quality Management System Regulation (QMSR)?

- When is the mandatory deadline to transition from QSR to QMSR?

- How does the new rule align with the global standard ISO 13485?

- Why is simply having an ISO 13485 certificate not enough for compliance?

- Which specific U.S. requirements are being kept in the new QMSR?

- What are the biggest challenges in harmonizing global quality documents?

- What is the first step your company should take to prepare for the 2026 deadline?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. Navigating the FDA's transition to the QMSR while managing global registrations requires expert strategy. We develop efficient pathways for regulatory approval, using advanced AI to compile and manage technical dossiers that meet both new QMSR and international standards. Our local experts in over 30 markets ensure your quality systems are compliant globally. Let us streamline your transition and accelerate your global market access. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the critical capacity crisis among Notified Bodies under the EU's Medical Device Regulation (MDR). We explore how the stringent requirements of the MDR, combined with a reduction in the number of designated Notified Bodies, have created a massive bottleneck for certifying new and legacy medical devices. We discuss the significant risk this poses to manufacturers, who face the possibility of their products being forced off the market as old certificates expire, and examine the European Commission's legislative response to extend the transition deadlines.

- What is the EU MDR Notified Body capacity crisis?

- Why are there multi-year delays for device certification in Europe?

- How did the transition from the MDD to the MDR create a market bottleneck?

- What are the crucial deadlines of May and September 2024 for legacy devices?

- Could your medical device be forced off the EU market due to expiring certificates?

- What steps did the European Commission take to prevent a widespread device shortage?

- How does the risk class of your device affect its new transition deadline?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access with local expertise and advanced AI, helping you navigate complex challenges like the EU MDR. Our services include developing efficient regulatory strategies, compiling technical dossiers with AI, and acting as your local representative in over 30 markets. We help you meet critical deadlines and maintain market presence. For support with your global expansion, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode dives into one of the most significant challenges facing medical device manufacturers in 2026—the mandatory EUDAMED registration deadline. We break down what the May 2026 milestone means, the complexities of uploading technical and Unique Device Identification (UDI) data, and the critical steps companies must take now to avoid being locked out of the European Union market.

Key Questions:

- What is the EUDAMED and why is it critical for EU market access?

- When is the final deadline for mandatory EUDAMED registration?

- What specific data, including UDI information, must be uploaded?

- What are the consequences of failing to meet the 2026 EUDAMED requirements?

- How does the new database impact post-market surveillance and transparency?

- What are the biggest data management challenges manufacturers face with this new system?

- How can you prepare your technical dossiers for a seamless EUDAMED submission?

Struggling to prepare for complex regulatory shifts like the EUDAMED deadline? Pure Global offers end-to-end consulting for MedTech and IVD companies, streamlining global market access. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, ensuring compliance with evolving standards. We act as your local representative in over 30 markets, including the EU, managing the entire registration process. To secure your market presence and navigate deadlines with confidence, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed breakdown of the medical device registration fees charged by Singapore's Health Sciences Authority (HSA). We cover the standard application fee and the specific evaluation costs for Class B, Class C, and Class D devices. The host explains how different evaluation routes—such as Full, Abridged, Expedited, and Immediate—impact the final cost and how leveraging prior approvals from reference agencies can lead to significant savings.

- What are the latest HSA registration fees for medical devices in Singapore as of August 2024?

- How do evaluation costs differ between Class B, Class C, and Class D devices?

- What is the difference in cost between a Full, Abridged, and Expedited evaluation route?

- Can prior approval from the US FDA or a European Notified Body reduce my Singapore registration fees?

- What is the standard application fee for all device classes?

- How can a strategic approach to registration save thousands of dollars per application?

- What costs are not included in the official HSA fees?

Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies looking to enter markets like Singapore. Our team of local experts, combined with advanced AI and data tools, can help you develop the most efficient regulatory strategy, prepare your technical dossier, and act as your local representative. We streamline the global market access process, helping you navigate complex fee structures and regulatory requirements to get your product to market faster. For more information, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Singapore's mandatory Good Distribution Practice for Medical Devices (GDPMDS) certification. We explore the governing standard, SS 620:2016, and explain why it is an essential requirement enforced by the Health Sciences Authority (HSA) for any company seeking to import or wholesale medical devices in this key Asian market. Learn about the core components of the standard, from quality management systems to traceability and storage, to ensure your supply chain is compliant.

- What is GDPMDS and why is it mandatory for market access in Singapore?

- How does the SS 620:2016 standard impact medical device importers and wholesalers?

- What are the key pillars of a compliant Quality Management System under GDPMDS?

- Why is traceability a critical component of Singapore's distribution requirements?

- What role does the Health Sciences Authority (HSA) play in enforcing these regulations?

- Are there specific requirements for storage, stock rotation, and handling recalls?

Pure Global offers end-to-end regulatory consulting to streamline global market access for MedTech and IVD companies. We act as your local representative in over 30 markets, including Singapore, developing efficient regulatory strategies and using advanced AI to compile technical dossiers. This ensures you meet critical requirements like GDPMDS for faster approvals. Our experts manage the entire process, from initial submission to post-market surveillance, ensuring your continued compliance. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your market entry.